Home Analyst Ratings

Analyst Ratings

Random

Analyst Activity – Wedbush Reiterates Outperform on CBRE Group (NYSE:CBG)

ME Staff - August 2, 2017

Adecoagro SA (NYSE:AGRO) has coverage initiated with a Neutral rating

Analyst Activity – Morgan Stanley Raises Its Price Target On Kansas City Southern (NYSE:KSU) to $102.00

Analyst Activity – Oppenheimer Reiterates Buy on Urogen Pharma (NASDAQ:URGN) (NASDAQ:URGN)

Analyst Activity – National Securities Reiterates Buy on Eagle Point Credit (NYSE:ECC)

Analyst Activity – KeyCorp Reiterates Buy on Cray (NASDAQ:CRAY)

ME Staff - January 19, 2018

Analyst Activity – Credit Suisse Group Raises Its Price Target On...

ME Staff - May 9, 2018

Analyst Activity – Daiwa Capital Markets Initiates Coverage On NASDAQ:HTHT –...

ME Staff - May 29, 2018

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has coverage initiated with a Overweight ➝...

ME Staff - October 1, 2018

Analyst Upgrades – Biogen (NASDAQ:BIIB) Stock Gets Upgraded By Mizuho from...

ME Staff - October 17, 2017

Analyst Activity – Deutsche Bank Lowers Its Price Target On NASDAQ:SMPL...

ME Staff - April 11, 2018

Aerie Pharmaceuticals Inc (NASDAQ:AERI) had its Average ➝ Outperform rating reiterated...

ME Staff - July 2, 2019

Analyst Activity – Northland Securities Initiates Coverage On NASDAQ:CEVA – CEVA...

ME Staff - June 5, 2018

Analyst Activity – Royal Bank Of Canada Reiterates Sector Perform on...

ME Staff - July 26, 2017

Analyst Activity – UBS Initiates Coverage On NASDAQ:ULTA – Ulta Beauty...

ME Staff - May 16, 2018

12 3...2,175 Page 1 of 2,175

/* */

EDITOR PICKS

GW Deal With Jazz Spurs Pot Stock Wave, a Look at...

February 11, 2021

Short Squeezes On the Left, Covid Stocks on the Right, 4...

January 29, 2021

Market Morning: Brexit Finale, Microsoft Momentum Stall, $2.4 Trillion Spending On...

December 7, 2020

Weekly Biotech Report covering – Opko Health Inc (NYSE:OPK) Intercept...

April 11, 2016

Facebook Inc – (NASDAQ:FB) Might Be Moving Away From Its...

April 8, 2016

Biotechnology Movers: Here’s Why Citius Pharmaceuticals Inc (NASDAQ:CTXR) Is Running Right...

November 8, 2017

ABOUT US

Market Exclusive offers the latest financial news and analysis for selected US stocks and securities. We are an investor driven research platform where new investment ideas from a exclusively selected group of seasoned investment analysts and qualified members from various disciplines are able to deliver their investment thesis’ across various industries and sectors. Our burgeoning team is comprised of individuals with strong backgrounds from various disciplines and businesses. Our goal is to provide an exclusive forum for contributors and users to leverage the knowledge base in order to make smarter investing decisions. At Market Exclusive, we believe that quality information from experienced well seasoned contributors provide our members with an edge that allows them to make wise investment choices. Market Exclusive is not a registered investment broker/dealer. The content on this site is for informational purposes only. Additionally, the content on this site does not represent the views of Market Exclusive and is solely a representation of the authors who publish them. Before investing in any security you should do your own due diligence and consult with a registered broker or financial advisor.